BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31848724)

  • 21. Radiomic Features Based on MRI Predict Progression-Free Survival in Pediatric Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma.
    Wagner MW; Namdar K; Napoleone M; Hainc N; Amirabadi A; Fonseca A; Laughlin S; Shroff MM; Bouffet E; Hawkins C; Khalvati F; Bartels U; Ertl-Wagner BB
    Can Assoc Radiol J; 2023 Feb; 74(1):119-126. PubMed ID: 35768942
    [No Abstract]   [Full Text] [Related]  

  • 22. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes.
    Saratsis AM; Kambhampati M; Snyder K; Yadavilli S; Devaney JM; Harmon B; Hall J; Raabe EH; An P; Weingart M; Rood BR; Magge SN; MacDonald TJ; Packer RJ; Nazarian J
    Acta Neuropathol; 2014; 127(6):881-95. PubMed ID: 24297113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
    van den Bent M; Saratsis AM; Geurts M; Franceschi E
    Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.
    Mueller S; Jain P; Liang WS; Kilburn L; Kline C; Gupta N; Panditharatna E; Magge SN; Zhang B; Zhu Y; Crawford JR; Banerjee A; Nazemi K; Packer RJ; Petritsch CK; Truffaux N; Roos A; Nasser S; Phillips JJ; Solomon D; Molinaro A; Waanders AJ; Byron SA; Berens ME; Kuhn J; Nazarian J; Prados M; Resnick AC
    Int J Cancer; 2019 Oct; 145(7):1889-1901. PubMed ID: 30861105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
    Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
    Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
    Anderson JL; Muraleedharan R; Oatman N; Klotter A; Sengupta S; Waclaw RR; Wu J; Drissi R; Miles L; Raabe EH; Weirauch ML; Fouladi M; Chow LM; Hoffman L; DeWire M; Dasgupta B
    Neuro Oncol; 2017 Aug; 19(8):1068-1078. PubMed ID: 28339768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
    Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
    Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
    Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
    Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma.
    Thomas L; Smith N; Saunders D; Zalles M; Gulej R; Lerner M; Fung KM; Carcaboso AM; Towner RA
    J Transl Med; 2020 Nov; 18(1):424. PubMed ID: 33168005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
    Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
    J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of
    Tinkle CL; Duncan EC; Doubrovin M; Han Y; Li Y; Kim H; Broniscer A; Snyder SE; Merchant TE; Shulkin BL
    J Nucl Med; 2019 Mar; 60(3):312-319. PubMed ID: 30072503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.
    Vitanza NA; Monje M
    Curr Treat Options Neurol; 2019 Jul; 21(8):37. PubMed ID: 31290035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commentary on "Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes".
    Jansen MH; Veldhuijzen van Zanten SE; Heymans MW; Hargrave D; Kramm CM; Van Vuurden DG
    Acta Neuropathol; 2016 May; 131(5):793-4. PubMed ID: 27026412
    [No Abstract]   [Full Text] [Related]  

  • 35. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
    Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
    Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rare Diffuse Intrinsic Pontine Glioma Metastasis Throughout the Brain and Spine.
    Lu VM; Brown DA; Daniels DJ
    World Neurosurg; 2020 Aug; 140():301-302. PubMed ID: 32474088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indolent course of brainstem tumors with K27M-H3.3 mutation.
    Baroni LV; Solano-Paez P; Nobre L; Michaeli O; Hawkins C; Laughlin S; Bartels U; Ramaswamy V; Bouffet E
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28102. PubMed ID: 31793190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas.
    Schramm K; Iskar M; Statz B; Jäger N; Haag D; Słabicki M; Pfister SM; Zapatka M; Gronych J; Jones DTW; Lichter P
    Neuro Oncol; 2019 Jul; 21(7):867-877. PubMed ID: 30943283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric thalamic glioma with H3F3A K27M mutation, which was detected before and after malignant transformation: a case report.
    Ishibashi K; Inoue T; Fukushima H; Watanabe Y; Iwai Y; Sakamoto H; Yamasaki K; Hara J; Shofuda T; Kanematsu D; Yoshioka E; Kanemura Y
    Childs Nerv Syst; 2016 Dec; 32(12):2433-2438. PubMed ID: 27392443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.